4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10 ...

Introduces 2025 full year revenue guidance of $180 million to $200 million, a 17% increase in revenue growth over 2024, and core adjusted earnings per diluted share of $6.00 to $6.25 Twelve commercial ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and ...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd ...

The FDA approved ensifentrine (Ohtuvayre; Verona) for COPD in June. It is a phosphodiesterase-3 and phosphodiesterase-4 inhibitor indicated for maintenance treatment of COPD in adults.₁₁ Two ...

This impressive performance was largely driven by $10.1 million in milestone payments, attributed to the FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of ...

This impressive performance was largely driven by $10.1 million in milestone payments, attributed to the FDA approvals of Ohtuvayre and Capvaxive, as well as the conditional marketing approval of ...

The revenue was entirely generated from sales of Ohtuvayre, the company's sole marketed product. Following these results, H.C. Wainwright maintained a Buy rating on Verona Pharma shares and raised ...